Struggling with frequent bathroom trips or a weak urine stream? Learn how to manage BPH with personalized care, from ...

There is a significant positive association between dietary calcium intake and benign prostatic hyperplasia (BPH), according to a study published online May 30 in Translational Andrology and Urology.

Chicago, Sept. 24, 2025 (GLOBE NEWSWIRE) -- The global benign prostatic hyperplasia surgical treatment market was valued at US$ 10.5 billion in 2024 and is expected to reach us$ 16.5 billion by 2033, ...

Discover a study showing how urethra-sparing robot-assisted simple prostatectomy preserves ejaculatory function while ...

Entadfi is a fixed-dose combination of finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. The Food and Drug Administration (FDA) has approved Entadfi ...

Benign prostatic hyperplasia (BPH) is an extremely common disease of older men, occurring in more than 70 percent of men over the age of 60. BPH results in substantial morbidity in this patient ...

Barcelona, February, 8th 2010.- Almirall informs that the European Commission has granted a marketing authorisation for silodosin. The product will be marketed in Spain by Almirall and Recordati under ...

DUBLIN--(BUSINESS WIRE)--The "Market Spotlight: Benign Prostatic Hyperplasia (BPH)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Benign Prostatic ...

Dutasteride for Low-Risk Prostate Cancer: Debate Heats Up The benign prostatic hyperplasia drug has the makings of a treatment for men on active surveillance, say the authors of a new study. No way, ...

Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are two of the most common prostate conditions among elderly men, with a significant percentage experiencing one or both conditions.